Pierard 1991

Methods	Individual randomised controlled trial
Participants	Dx: Seborrhoeic dermatitis lesions present at the hairline, eyebrow, forehead, nasolabial folds and retroauricular, presternal and intracapsular areas (physician diagnosis implied) Excluded: patients treated with antifungals or corticosteroids 2 weeks before start of the study, patients with only seborrhoeic dermatitis of the scalp, patients with serious concomitant disease, patients known to be unreliable
Interventions	Intervention: ketoconazole 2% emulsion applied to site twice daily for 28 days (n = 23) Control: placebo emulsion applied similarly (n = 16)
Outcomes	Global evaluation of cure Symptom severity scores for erythema, pruritus and scaling
Notes	Country: Belgium COI: No conflicts of interest were declared Symptom scores were reported as endpoint mean decreases in symptom score. No standard deviations were provided; therefore results were omitted from the data tables and were reported qualitatively in the relevant section
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Not reported
Baseline comparable?	Low risk	"Both groups were comparable for sex, age, weight, height and duration of infection"
Patient blinded?	Unclear risk	Not reported
Provider blinded?	Unclear risk	Not reported
Outcome assessor blinded?	Unclear risk	Not reported
Co-interventions avoided?	Unclear risk	Not reported
Compliance acceptable?	Unclear risk	Not reported
Drop-out acceptable?	Unclear risk	2 drop-outs in the ketoconazole group vs 9 in the placebo group
Selective outcome reporting acceptable?	Unclear risk	All outcomes were reported
ITT?	Unclear risk	Not reported